Highbridge Capital Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Highbridge Capital Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-86,486	Closed	-$347K	–	1994
2015 Q4	$347K	Buy	86,486 +28,703	+50%	+$132K	0.01%	1134
2015 Q3	$265K	Buy	+57,783	New	+$302K	﹤0.01%	1278
2014 Q2	–	Sell	-41,352	Closed	-$985K	–	1376
2014 Q1	$985K	Buy	+41,352	New	+$600K	0.01%	555
2013 Q4	–	Sell	-12,112	Closed	-$161K	–	1444
2013 Q3	$161K	Buy	+12,112	New	+$191K	﹤0.01%	1198

Other funds holding ECYT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Highbridge Capital Management's ECYT Position: Q1 2016 in Review

Highbridge Capital Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q1 2016, closing a stake of 86,486 shares — an estimated $347K sold.

Highbridge Capital Management first reported a position in ECYT in Q3 2013 and held it in 4 quarters. The position peaked at $985K in Q1 2014. 97 funds tracked by Wall St. Rank hold ECYT as of Q1 2016.

Highbridge Capital Management reported no remaining Endocyte, Inc. Common Stock position as of Q1 2016 after selling out during the quarter.
Highbridge Capital Management sold 86,486 Endocyte, Inc. Common Stock shares in Q1 2016, an estimated $347K.
Highbridge Capital Management first reported a position in Endocyte, Inc. Common Stock in Q3 2013 and held it in 4 quarters.
Highbridge Capital Management's Endocyte, Inc. Common Stock position peaked at $985K in Q1 2014.
97 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q1 2016.

Based on Highbridge Capital Management's 13F filing for Q1 2016, filed 16 May 2016.